Sign in
Download Opera News App

COVID

 

Health COVID

 

Another Covid Vaccine Linked To Blood Clots

More than 6.8 million doses were given as of April 12 in the United States of America for the J&J vaccine.

On Tuesday US FDAs advised a stop to the use of the COVID-19 vaccine by Johnson & Johnson after 6 recipients have developed a rare blood clot condition in a fresh retrogression of global pandemic response efforts.

It was a week after European regulators stated that they had discovered a potential correlation between the COVID-19 vaccine from AstraZeneca and an unusual issue of blood coagulation that had resulted in few deaths. 

The single-dose vaccine of Johnson and Johnson (J&J) – more than two doses of COVID-19 injections – is seen as vital tools for the fight against a pandemic that took more than three million lives. The low-cost vaccine is also considered essential in AstraZeneca. 

The advisory committee at the CDC will meet on Wednesdays to discuss the cases related to the vaccine, and it will review the report, according to the agencies, by the US Food and Drug Administration (FDA).

All six were females between 18 and 48 years of age, with symptoms occurring 6 to 13 days after vaccination. 

There was in comcombinationth low blood platelets a blood clot form known as cerebral venous sinus thrombosis (CVST) (thrombocytopenia).

The CDC and the FDA reported that the adverse events seemed particularly unusual. 

J&J said it cooperated closely with the regulators and no clear causal link between events and the COVID-19 vaccine produced by its Janssen group was identified. 

The New York Times confirmed, citing officials, that one woman died and another in Nebraska has been in critical shape. 

By April 12, the United States had received more than 6.8 million doses of J&J the cine. 

The US change comes less than a week after Europe's drug regulator says that four people in the United States who had been fired checked for unusual blood clots. 

European officials have said J&J has started to deliver its vaccine COVID-19 to EU countries on Monday and pledged 55 million block doses at the end of June and another 120 million in the third quarter. 

The European Medicines Regulator is still recommending the use of COVID-19 the vaccine from AstraZeneca, who said that the benefits outweigh the risks. However, some EU Member States have limited their use to certain age groups. 

Australia does not have plans to include J&J coronavirus in their immunization drive on Tuesday as it moves away from obtaining the vaccines for possible linkages to blood clots under review. Australia has no plans.

Content created and supplied by: Brenda254 (via Opera News )

CDC European FDA Johnson US

COMMENTS

Load app to read more comments